President Biden took an important step toward safeguarding the U.S. economy with last year’s Executive Order No. 14,036, “Promoting Competition in the American Economy,” aimed at promoting competition at home in the face of unfair competitive pressure… Read More »
Sen. Patrick Leahy, D-Vt. , introduced a bill last September that would make it harder for America’s most brilliant scientists and inventors to create new world-changing, life-saving products. That isn’t lawmakers’ intention, of course. The authors of… Read More »
As we mark World IP Day, it provides an opportunity to marvel at the critical role the American system of protecting IP, particularly patents, has played in the United States’ global innovation leadership. Unfortunately, recent years have… Read More »
A bipartisan group of senators just introduced a bill to crack down on Chinese companies that steal hundreds of billions of dollars in American intellectual property every year. Unfortunately, another urgent threat to American inventors’ IP is emerging here… Read More »
Even as bipartisan support grows in Congress for legislation aimed at curbing the economic power of Big Tech, the Biden Administration’s Department of Justice, with tacit support from the U.S. Patent & Trademark Office (USPTO) and the… Read More »
In 2011, I jointly authored with Sen. Patrick Leahy (D-Vt.) the bill that would become the Leahy–Smith America Invents Act (AIA). The AIA was the most extensive reform of the U.S. patent system in 60 years. A… Read More »
This article is contributed by Paul R. Michel. America can’t outcompete low-wage countries when it comes to manufacturing cheap, mass-produced widgets. Our labor and regulatory costs are simply too high. But we can — and historically have… Read More »
If your car starts to smoke and sputter, you’d take it to an auto repair shop right away. The U.S. patent system — the engine driving the country’s innovation economy for more than 200 years — is sputtering… Read More »
The FDA recently authorized two antiviral pills, Pfizer’s Paxlovid and Merck’s Lagevrio, to treat Covid-19. The treatments can reduce the risk of death in high-risk patients by up to 89% and 30%, respectively. These drugs could effectively end… Read More »
In November, a district court judge in Northern California dismissed a lawsuit those firms had filed against the U.S. Patent and Trademark Office. They were trying to strip away USPTO’s discretionary authority to consider – or not… Read More »
